Valuation: Atossa Therapeutics, Inc.

Market Cap 25.95M 22.41M 21.06M 19.15M 36.01M 2.48B 36.6M 247M 96.47M 1.24B 97.41M 95.3M 4.13B P/E 2026 *
-0.68x
P/E 2027 * -0.83x
Enterprise Value 25.95M 22.41M 21.06M 19.15M 36.01M 2.48B 36.6M 247M 96.47M 1.24B 97.41M 95.3M 4.13B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-0.39%
1 week+8.05%
Current month+23.19%
1 month+6.69%
3 months-47.42%
6 months-39.29%
Current year-71.19%
1 week 2.27
Extreme 2.27
2.69
1 month 2.05
Extreme 2.05
2.69
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
64.65
10 years 1.7
Extreme 1.7
715.5
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
20/1/26 Free

Chief Executive Officer

1,281,674 0.9922%
20/1/26
Ensisheim Partners LLC
OtherCompany 0 0%
14/10/25 Free

Chief Financial Officer

578,000 0.4595%
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%+8.05%-78.11%-80.83% 25.95M
-1.78%-1.68%+1.48%+17.26% 48.42B
+0.85%-0.70%+460.88%+581.30% 43.66B
-2.40%-0.23%+8.13%+80.67% 39.51B
-2.01%-0.85%+23.85%+9.97% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+126.36% 16.15B
+0.49%+0.92%+4.11%+26.37% 14.16B
-0.43%+4.70%+78.74%+38.66% 13.37B
Average -0.64%+1.24%+60.67%+95.33% 26.32B
Weighted average by Cap. -0.91%+0.59%+95.81%+140.24%

Financials

2026 *2027 *
Net sales - -
Net income -34.89M -30.14M -28.32M -25.76M -48.42M -3.34B -49.22M -332M -130M -1.67B -131M -128M -5.55B -38.03M -32.84M -30.86M -28.07M -52.77M -3.64B -53.64M -362M -141M -1.82B -143M -140M -6.05B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
14/08/26 USD 2.600 +1.56% 96,120
13/08/26 USD 2.560 +8.94% 83,113
12/08/26 USD 2.350 -0.42% 31,349
11/08/26 USD 2.360 -0.42% 56,704
10/08/26 USD 2.370 +0.42% 69,086
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.600USD
Average target price
18.67USD
Spread / Average Target
+617.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock